Cidofovir

Cidofovir

Clinical data
Trade names	Vistide
AHFS/Drugs.com	Monograph
License data	EU EMA: Vistide US FDA: Cidofovir
Pregnancy category	AU: D US: C (Risk not ruled out)
Routes of administration	IV
ATC code	J05AB12 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	complete
Protein binding	<6%
Biological half-life	2.6 hours (active metabolites: 15-65 hours)
Excretion	renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid.
Identifiers
IUPAC name ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
CAS Number	113852-37-2 Y
PubChem (CID)	60613
DrugBank	DB00369 Y
ChemSpider	54636 Y
UNII	768M1V522C Y
ChEBI	CHEBI:3696 Y
ChEMBL	CHEMBL152 Y
NIAID ChemDB	001049
ECHA InfoCard	100.166.433
Chemical and physical data
Formula	C8H14N3O6P
Molar mass	279.187 g/mol
3D model (Jmol)	Interactive image
Specific rotation	-97.3
Melting point	260 °C (500 °F)
SMILES O=C1/N=C(\C=C/N1C[C@H](OCP(=O)(O)O)CO)N
InChI InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1 Y Key:VWFCHDSQECPREK-LURJTMIESA-N Y

renal

Cidofovir (brand name Vistide) is an injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS.

Cidofovir was approved for medical use in 1996.

Its only indication that has received regulatory approval worldwide is cytomegalovirus retinitis. Cidofovir has also shown efficacy in the treatment of aciclovir-resistant HSV infections. Cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy with successful case reports of its use. Despite this, the drug failed to demonstrate any efficacy in controlled studies. Cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases.Brincidofovir, a cidofovir derivative with much higher activity against smallpox that can be taken orally has been developed. It has inhibitory effects on varicella-zoster virus replication in vitro although no clinical trials have been done to date, likely due to the abundance of safer alternatives such as aciclovir. Cidofovir shows anti-BK virus activity in a subgroup of transplant recipients. Cidofovir is being investigated as a complementary intralesional therapy against papillomatosis caused by HPV.

It first received FDA approval on the 26th of June 1996,TGA approval on the 30th of April 1998 and EMA approval on the 23rd of April 1997.

It has been suggested as an antitumour agent, due to its suppression of FGF2.